What is HC Wainwright's Estimate for CMPX FY2028 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Investment analysts at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for Compass Therapeutics in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.94 for the year, up from their prior estimate of $0.85. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.42) per share.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03.

CMPX has been the topic of several other reports. Wedbush reaffirmed an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a report on Wednesday, August 7th. LADENBURG THALM/SH SH raised Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 price objective on the stock in a research note on Monday, September 16th.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX traded down $0.10 during mid-day trading on Thursday, reaching $1.59. 668,605 shares of the company's stock were exchanged, compared to its average volume of 434,151. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The firm has a market capitalization of $218.77 million, a price-to-earnings ratio of -4.47 and a beta of 0.92. The business's fifty day moving average price is $1.75 and its 200-day moving average price is $1.42.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CMPX. Rovin Capital UT ADV acquired a new stake in Compass Therapeutics during the third quarter worth approximately $25,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics during the 3rd quarter worth approximately $30,000. SG Americas Securities LLC increased its stake in shares of Compass Therapeutics by 16.6% in the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock valued at $71,000 after acquiring an additional 5,515 shares in the last quarter. Bleakley Financial Group LLC acquired a new position in shares of Compass Therapeutics during the 1st quarter valued at $80,000. Finally, Cubist Systematic Strategies LLC bought a new position in Compass Therapeutics during the second quarter worth $41,000. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.